Literature DB >> 8399489

Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice.

M Manthorpe1, F Cornefert-Jensen, J Hartikka, J Felgner, A Rundell, M Margalith, V Dwarki.   

Abstract

Direct injection of nonviral, covalently closed circular plasmid DNA into muscle results in expression of the DNA in myofiber cells. We have examined the expression of firefly luciferase DNA constructs injected into adult murine skeletal muscle. Considerable variation in luciferase enzyme expression was noted among constructs with different regulatory elements, among different batches of the same DNA construct, and among similar transfection experiments performed at different times. This variation was minimized by using single batches of plasmid DNA and by performing comparable sets of experiments concurrently. A quantitative experimental protocol was defined for comparing various aspects of the transfection process. We report that a luciferase construct containing the human cytomegalovirus immediate-early gene promoter plus intron A (a construct termed "p-CMVint-lux") showed the highest expression among several constructs tested. Dose-response and time course analyses of p-CMVint-lux DNA injections showed that maximal luciferase expression was achieved with 25 micrograms of DNA at 7-14 days post-injection. Selected manipulations of the transfection process were examined for their influence on luciferase expression. Variations in the rate of DNA injection, needle size, injection volume, and vehicle temperature had no significant effect on luciferase expression. The presence of endotoxin, cationic peptide, muscle stimulants or relaxants, vasoconstrictors, metal chelators, or lysosomal lytic reagents had no significant effect on expression. However, linearization of the DNA, injection of the DNA in water rather than saline, or inclusion of a DNA intercalating agent nearly abolished luciferase expression. And finally, increasing the injection dose by giving multiple injections over a 10-day period increased expression proportionally to the number of injections.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8399489     DOI: 10.1089/hum.1993.4.4-419

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  72 in total

1.  Sequence requirements for plasmid nuclear import.

Authors:  D A Dean; B S Dean; S Muller; L C Smith
Journal:  Exp Cell Res       Date:  1999-12-15       Impact factor: 3.905

Review 2.  Dendritic cell delivery of plasmid DNA. Applications for controlled genetic immunization.

Authors:  R J Mumper; H C Ledebur
Journal:  Mol Biotechnol       Date:  2001-09       Impact factor: 2.695

3.  Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response.

Authors:  P J Lewis; L A Babiuk
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 4.  Electroporation of the vasculature and the lung.

Authors:  David A Dean
Journal:  DNA Cell Biol       Date:  2003-12       Impact factor: 3.311

Review 5.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

6.  Analysis of DNA-vaccinated fish reveals viral antigen in muscle, kidney and thymus, and transient histopathologic changes.

Authors:  Kyle A Garver; Carla M Conway; Diane G Elliott; Gael Kurath
Journal:  Mar Biotechnol (NY)       Date:  2005-07-22       Impact factor: 3.619

7.  Plasmid delivery in vivo from porous tissue-engineering scaffolds: transgene expression and cellular transfection.

Authors:  Jae-Hyung Jang; Christopher B Rives; Lonnie D Shea
Journal:  Mol Ther       Date:  2005-09       Impact factor: 11.454

Review 8.  Intracellular trafficking of plasmids for gene therapy: mechanisms of cytoplasmic movement and nuclear import.

Authors:  Erin E Vaughan; James V DeGiulio; David A Dean
Journal:  Curr Gene Ther       Date:  2006-12       Impact factor: 4.391

9.  Angiogenic potential of microvessel fragments is independent of the tissue of origin and can be influenced by the cellular composition of the implants.

Authors:  Sara S Nunes; Laxminarayanan Krishnan; Carter S Gerard; Jacob R Dale; Melissa A Maddie; Richard L Benton; James B Hoying
Journal:  Microcirculation       Date:  2010-10       Impact factor: 2.628

10.  Stability and functional effectiveness of phosphorothioate modified duplex DNA and synthetic 'mini-genes'.

Authors:  S A Ciafrè; M Rinaldi; P Gasparini; D Seripa; L Bisceglia; L Zelante; M G Farace; V M Fazio
Journal:  Nucleic Acids Res       Date:  1995-10-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.